Needham Maintains Buy on Inari Medical, Lowers Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a Buy rating on Inari Medical (NASDAQ:NARI) but lowers the price target from $72 to $57.

May 01, 2024 | 9:43 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Needham maintains a Buy rating on Inari Medical but reduces the price target from $72 to $57.
The reduction in price target by Needham, despite maintaining a Buy rating, could lead to short-term negative sentiment among investors, potentially impacting NARI's stock price negatively as the market adjusts to the new price target.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100